Gil Yosipovitch, MD, discusses how barzolvolimab, a novel mast cell-depleting therapy targeting the KIT receptor, showed promising efficacy and safety results in a phase 2 trial for chronic spontaneous urticaria (CSU), achieving complete response in over 50% of patients within 12 weeks with sustained disease control lasting 28 weeks after treatment discontinuation.
